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Fluoxetine (Prozac), an antidepressant known to selectively inhibit serotonin reuptake,
is widely used to treat mood disorders in women suffering from depression during
pregnancy and postpartum period. Several lines of evidence suggest that this drug,
which crosses the human placenta and is secreted into milk during lactation, exerts its
action not only by interfering with serotoninergic but also with GABAergic transmission.
GABA is known to play a crucial role in the construction of neuronal circuits early in
postnatal development. The immature hippocampus is characterized by an early type
of network activity, the so-called Giant Depolarizing Potentials (GDPs), generated by
the synergistic action of glutamate and GABA, both depolarizing and excitatory. Here
we tested the hypothesis that fluoxetine may interfere with GABAergic signaling during
the first postnatal week, thus producing harmful effects on brain development. At
micromolar concentrations fluoxetine severely depressed GDPs frequency (IC50 22μM)
in a reversible manner and independently of its action on serotonin reuptake. This effect
was dependent on a reduced GABAergic (but not glutamatergic) drive to principal cells
most probably from parvalbumin-positive fast spiking neurons. Cholecystokinin-positive
GABAergic interneurons were not involved since the effects of the drug persisted when
cannabinoid receptors were occluded with WIN55,212-2, a CB1/CB2 receptor agonist.
Fluoxetine effects on GABAergic transmission were associated with a reduced firing
rate of both principal cells and interneurons further suggesting that changes in network
excitability account for GDPs disruption. This may have critical consequences on the
functional organization and stabilization of neuronal circuits early in postnatal development.
Keywords: fluoxetine, immature hippocampus, GDPs, spontaneous action potential-dependent release of GABA,
spontaneous firing of principal cells and interneurons
INTRODUCTION
Fluoxetine (Prozac) is a selective serotonin reuptake inhibitor
widely used for the treatment of depressive disorders (Wong
et al., 1974, 1995). According to the “monoamine hypothesis”
of depression, this drug would act by enhancing the extra-
cellular serotonin levels and function in particular brain areas
targeted by the serotoninergic system such as the frontal cor-
tex and the hippocampus, thought to be involved in the con-
trol of emotion, memory, and cognition (Krishnan and Nestler,
2008). However, whether fluoxetine-induced amelioration of
mood disorders is exclusively linked to potentiation of sero-
toninergic activity or requires other neurotransmitters involved
in plastic changes of neuronal connectivity is still a matter of
debate (Castrén, 2005). Evidence has been provided that in the
adult visual system, chronic administration of fluoxetine is able
to reinstate ocular dominance plasticity and promote recovery
of visual function in amblyopic animals, an effect associated
with a BDNF-dependent reduction of cortical inhibition (Maya
Vetencourt et al., 2008, 2011, 2012). Recent findings have indeed
indicate that fluoxetine affects GABAergic transmission support-
ing a casual relationship between a dysfunction of GABAergic
signaling and depressive disorders (Luscher et al., 2011). Thus,
the acute and chronic administration of two major antidepres-
sant, imipramine and fluoxetine, has been shown to impair
GABAA-mediated perisomatic inhibition mediated by parval-
bumin (PV)-positive fast spiking interneurons, and to disrupt
γ-oscillations, further suggesting a new mechanism of action
of these drugs in controlling mood disorders (Méndez et al.,
2012).
At late embryonic, early postnatal stages of development the
inhibitory transmitter GABA depolarizes and excites targeted cells
in the hippocampus because of an initially high intracellular chlo-
ride concentration (Cherubini et al., 1991; Ben-Ari et al., 2012).
The depolarizing and excitatory action of GABA, in synergy with
that of glutamate is instrumental for initiating synchronized net-
work activity under the form of giant depolarizing potentials or
GDPs (Ben-Ari et al., 1989). GDPs, which constitute a primor-
dial form of synchrony between neurons, have been proposed to
be the in vitro counterpart of “sharp waves” recorded in rat pups
in vivo during immobility periods, sleep, and feeding (Leinekugel
et al., 2002). Calcium transients associated with GDPs are cru-
cial for enhancing, in a Hebbian type of way, synaptic efficacy at
emerging glutamatergic (Mohajerani et al., 2007) and GABAergic
synapses (Kasyanov et al., 2004).
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Recent data indicate that in the immature CA3 hippocam-
pal region, a few early generated GABAergic interneurons are
able to affect network dynamics acting as functional hubs to
pace the activity of hundreds of cells via their extensive axonal
arborizations (Bonifazi et al., 2009; Picardo et al., 2011; Allene
et al., 2012). In addition, among the large variety of GABAergic
interneurons present in the hippocampus (Klausberger and
Somogyi, 2008), those generated later from the medial ganglionic
eminence, belonging mainly to parvalbumin-containing periso-
matic targeting cells (Cossart, 2011), constitute together with
cholecystokinin-positive basket cells the main source of spon-
taneous GABAA-mediated synaptic events recorded from CA3
principal cells (Freund and Katona, 2007). The latter express
cannabinoid receptor type 1. Spontaneously occurring synaptic
activity may summate to reach the threshold for action potential
generation thus contributing to GDPs onset (Ben-Ari et al., 2012).
Fluoxetine is the most commonly prescribed antidepressant
drug for women suffering from depression during pregnancy and
the postpartum period. However, this drug, which being highly
lipophilic crosses the human placenta (Heikkine et al., 2002) and
is secreted with milk (Davanzo et al., 2011) may exert harmful
effects on the development of fetuses or neonates, respectively.
These exhibit an increased risk to develop neuro-developmental
disorders and to experience behavioral deficits (Nulman et al.,
2002; Oberlander et al., 2009). In addition, animal studies have
shown that chronic treatment of pregnant rats with fluoxe-
tine alters the offsprings response of the hippocampus to stress
(Olivier et al., 2011a,b; Pawluski et al., 2012).
Here, we tested the hypothesis that fluoxetine affects
GABAergic signaling during the first week of postnatal life when
most of plastic changes occur. We found that the antidepressant
reversibly blocks GABAA-mediated GDPs in a concentration-
dependent way and independently of its effects on the amine
reuptake systems.
MATERIALS AND METHODS
ETHICAL APPROVAL
All experiments were performed in accordance with the
European Community Council Directive of November 24, 1986
(86/609EEC) and were approved by the local authority veterinary
service and by SISSA ethical committee. All efforts were made to
minimize animal suffering and to reduce the number of animal
used.
HIPPOCAMPAL SLICES PREPARATION
Wistar rats were decapitated after being anesthetized with CO2.
Hippocampal slices were obtained from at postnatal (P) days
P2-P6 (day 0 was considered the day of birth) animals using
a standard protocol (Caiati et al., 2010). Briefly, the brain was
quickly removed from the skull and placed in ice-cold ACSF con-
taining (in mM): NaCl 130, KCl 3.5, NaH2PO4 1.2, MgCl2 1.3,
CaCl2 2, Glucose 24, NaHCO3 27, saturated with 95% O2 and
5% CO2 (pH 7.3–7.4).
Transverse hippocampal slices (400μm thick) were cut with
a vibratome and stored at room temperature (20–24◦C) in a
holding bath containing the same solution as above. After a recov-
ery period of at least 1-h, an individual slice was transferred to
the recording chamber where it was continuously superfused with
oxygenated ACSF at 33–35◦C at the rate of 3–4ml min−1.
ELECTROPHYSIOLOGICAL RECORDINGS
Electrophysiological experiments were performed from CA3
principal cells or stratum radiatum interneurons in the CA3
area using the cell-attached and the whole-cell configuration of
the patch-clamp technique in current or voltage-clamp mode.
Neurons were visualized using an upright microscope (Olympus
BX51WI) equipped with differential interference contrast (DIC)
optics and infrared video camera.
Patched electrodes were pulled from borosilicate glass capil-
laries (Hingelberg, Malsfeld, Germany). They had a resistance
of 4–6M when filled with an intracellular solution contain-
ing (in mM): KCl 140, MgCl2 1, EGTA 0.5, HEPES 10, Mg
ATP 4, (pH 7.3; the osmolarity was adjusted to 290 mOsmol).
Glutamatergic postsynaptic currents were recorded using patch
pipettes filled with a solution containing the following (in mM):
120 Cs-MeSO4, 20KCl, 10HEPES, 0.5 EGTA, 0.3Na-GTP, and
4Mg-ATP 4, pH 7.2 (osmolality, 275–280mOsm).
Recordings weremade with a patch clamp amplifier (Axopatch
200A; Molecular Device, Sunnyvale, CA, USA). The stability of
the patch was checked by repetitively monitoring the input and
series resistance during the experiment. Cells exhibiting >15
changes in series resistance were excluded from the analysis. The
series resistance was<25 M and was not compensated.
Spontaneous glutamatergic and GABAergic postsynaptic cur-
rents were routinely recorded from a holding potential of−70mV
in the presence of bicuculline (10μM) and DNQX (20μM),
respectively. Miniature currents were recorded in the pres-
ence of TTX (1μM) to block sodium currents and propagated
action potentials. Spontaneous firing was recorded in the cell
attached mode from CA3 principal cells and stratum radiatum
interneurons.
DRUGS
Drugs used were: tetrodotoxin (TTX, purchased from Latoxan,
Valence, France), 6,7-dinitroquinoxaline-2,3-dione (DNQX),
bicuculline methiodide, biocytin, citalopram hydrobromide, ase-
napine maleate, WIN55,212-2 mesylate all purchased from Tocris
(Tocris Cookson Inc., UK); fluoxetine (gift of Prof. L. Maffei,
Pisa).
All drugs were dissolved in ACSF except DNQX that was dis-
solved in DMSO. The final concentration of DMSO in the bathing
solution was 0.1%. At this concentration, DMSO alone did not
modify the shape or the kinetics of synaptic currents. Reagents
were prepared as stock solutions and stored before use as aliquots
in tightly sealed vials at the recommended manufacturers’ tem-
perature. Drugs were applied in the bath via a three-way tap
system, by changing the superfusion solution to one differing only
in its drug(s) content). The ratio of flow rate to bath volume
ensured complete exchange within 2min.
DATA ACQUISITION AND ANALYSIS
Data were acquired and digitized with an A/D converter
(Digidata, 1200, Molecular Device, Sunnyvale, CA, USA) and
stored on a computer hard disk. Acquisition and analysis were
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performed with Clampfit 9 (Molecular Device, Sunnyvale, CA,
USA). Data were sampled at 20 kHz and filtered with a cut off
frequency of 2 kHz. The resting membrane potential (RMP) was
measured immediately after break-in and establishing whole-cell
recording. The membrane input resistance (Rin) was calculated
by measuring the amplitude of voltage responses to steady hyper-
polarizing current steps of increasing intensity, using the Clampfit
10.0 program (Molecular Device, Sunnyvale, CA, USA).
Spontaneous action potential-dependent and independent
(miniature) AMPA and GABAA-mediated postsynaptic currents
were analyzed using Clampfit 10.0 (Axon Instruments). This pro-
gram uses a detection algorithm based on a sliding template. The
template did not induce any bias in the sampling of events because
it was moved along the data trace by one point at a time and was
optimally scaled to fit the data at each position. The detection cri-
terion was calculated from the template-scaling factor and from
how closely the scaled template fitted the data.
Unless otherwise stated, data are presented as mean ± SEM.
Significance of differences was assessed by Student’s t-test, or
Wilcoxon signed rank test, as appropriate. A p value < 0.05 was
considered as significant.
RESULTS
FLUOXETINE REDUCES THE FREQUENCY OF GDPs
We first tested the effects of different concentrations of fluoxetine
on spontaneous network-driven events which represent a hall-
mark of developmental circuits (Ben-Ari et al., 2012). We focused
on the CA3 region of the hippocampus, because this region is cen-
trally involved in GDPs generation (Menendez de la Prida et al.,
1998; Bonifazi et al., 2009; Picardo et al., 2011; Allene et al., 2012).
Here, GABAergic interneurons with large axonal arborizations
operate as functional hubs able to synchronize large ensembles
of cells (Bonifazi et al., 2009).
GDPs occurred at the frequency of 0.08 ± 0.04Hz (n = 5).
As illustrated in Figures 1A,B, bath application of fluoxe-
tine (20μM), significantly reduced GDPs frequency (from
0.08 ± 0.04Hz to 0.045 ± 0.031Hz; n = 5; p = 0.021;
Figure 1B) without altering their shape (Figure 1A). Fluoxetine
did not affect the RMP (49 ± 3mV and 49 ± 2mV; n = 6;
p = 0.2, before and during the administration of the drug), or
the input resistance (475 ± 38M and 490 ± 41M, n = 6;
p = 0.87), before and during the administration of the drug)
of the recorded neurons. An almost complete recovery was
obtained 11 ± 4min after fluoxetine was washed out. The effect
of fluoxetine on GDPs was concentration dependent. Exposure
of individual slices to increasing concentrations of fluoxetine
(from 3 to 50μM) progressively reduced the frequency of GDPs.
While at the concentration of 1μM, known to efficiently block
monoamine reuptake (Kobayashi et al., 2008), fluoxetine failed to
affect correlated activity, at the concentration of 50μM it com-
pletely abolished GDPs. As shown in cumulative dose-response
curve of Figure 1C, fitting the experimental points with the Hill
equation gave an IC50 value of 22μM. This value is close to
that obtained after chronic administration of the antidepressant
which accumulates in the brain (Henry et al., 2005). Therefore in
the following experiments we used a concentration of fluoxetine
of 20μM, close to the IC50 value.
FIGURE 1 | Fluoxetine reduces the frequency of Giant Depolarizing
potentials. (A) GDPs recorded before, during and after (Wash) application
of fluoxetine (20μM). GDPs marked with an asterisk are shown on the right
on an expanded time scale. (B) Population graph of GDPs frequency before,
during and after application of fluoxetine. Columns represent the mean ±
SEM. (C) Fluoxetine depressed GDPs in a concentration-dependent way.
Each point represents the mean value of five individual experiments. Bars
are the SEM (they are often within the symbols). Data points were fitted
with the Hill equation (the IC50 value was 22μM).
To further elucidate whether the effects of fluoxetine on
GDPs were mediated by the indirect action on serotonin, we
occluded serotonin uptake with citalopram (1μM; Inoue et al.,
1996). This drug per se caused an increase of GDPs frequency
(from 0.078 ± 0.03Hz to 0.15 ± 0.035Hz; n = 5; p < 0.001;
Figures 2A,B), suggesting the existence of a tonic serotonin
component.
However, after incubating the slices for 30min with citalo-
pram, addition of fluoxetine significantly reduced the frequency
of GDPs of 70.8 ± 10.6%; n = 5; p = 0.02; (Figures 3A,C). This
value was not significantly different from that obtained with
fluoxetine alone (p = 0.3). Similarly, application of fluoxetine
in the presence of asenapine (0.2μM), a drug used for the
acute treatment of schizophrenia as well as bipolar disorders
which affects monoamine, histamine and muscarinic receptors
(McIntyre, 2010), significantly reduced GDPs frequency in a
way that was comparable to that found in the absence of the
drug (reduction of 62 ± 8%; n = 5; p = 0.03; Figures 3B,C). Like
citalopram, asenapine per se caused an enhancement of GDPs fre-
quency (from 0.06 ± 0.03Hz to 0.1 ± 0.026Hz; n = 5; p = 0.02;
Figures 2C,D).
These data clearly indicate that fluoxetine acts on GDPs inde-
pendently of serotonin action since its effects persisted in the
presence of citalopram, a selective serotonin uptake inhibitor and
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FIGURE 2 | Low concentrations of citalopram and asenapine enhance
GDPs frequency. (A) GDPs recorded before and during application of
citalopram (1μM). (B) Summary data for the results shown in A (n = 5;
p < 0.001). Each column represents the mean ± SEM. (C,D) as for (A,B)
but for asenapine (0.2μM; n = 5; p = 0.02).
after pharmacological occlusion of monoamine receptors with
asenapine.
FLUOXETINE ENHANCES THE FREQUENCY OF MINIATURE GABAergic
BUT NOT GLUTAMATERGIC CURRENTS
Since GDPs are generated by the synergistic action of GABA
and glutamate, both of which depolarizing and excitatory (Ben-
Ari et al., 1989; Cherubini et al., 1991), we next examined
whether changes in spontaneous miniature GABAA- and AMPA-
mediated postsynaptic currents (mGPSCs and mEPSCs, respec-
tively) could account for the effects of fluoxetine on GDPs.
Miniature GABAergic or glutamatergic currents were recorded in
the presence of TTX (1μM) and bicuculline or DNQX, respec-
tively. Miniature GPSCs occurred at the frequency of 1.55 ±
0.35Hz (n = 11). As shown in Figures 4A–C, application of
fluoxetine (20μM), significantly enhanced mGPSCs frequency
(from 1.55 ± 0.35Hz to 2.25 ± 0.46Hz; p = 0.002) without
affecting their amplitude (on average the mGPSCs amplitude
was 18.6 ± 3.9 pA and 16.2 ± 2.6 pA, before and after fluoxetine,
respectively; p = 0.17). This is clearly illustrated in the exam-
ple of Figure 4A and in the cumulative inter event interval (IEI)
plot of Figure 4B, where the distribution of mGPSCs obtained in
the presence of fluoxetine is shifted to the left respect to those
obtained in the absence of the drug (p < 0.05; K–S test) and in
the summary graph of Figure 4C.
Fluoxetine did not alter the frequency or amplitude of
mEPSCs. The frequency of mEPSCs was 0.9 ± 0.07Hz and
FIGURE 3 | The effects of fluoxetine on GDPs are independent of
serotonin uptake or monoamine action. (A) Citalopram, a selective
serotonin reuptake inhibitor, at the concentration of 1μM enhanced the
frequency of GDPs. Addition of fluoxetine (20μM) significantly reduced the
frequency of GDPs. (B) Asenapine, a monoamine receptors blocker, also
increased GDPs frequency that was reduced by subsequent addition of
fluoxetine. (C) Summary data for the results shown in (A) and (B).
Fluoxetine-induced reduction of GDPs frequency was similar when the
antidepressant was administered alone or together with citalopram or
asenapine (p = 0.17).
0.9 ± 0.04Hz, before and during fluoxetine, respectively (n = 5;
p = 0.5; Figures 4D–F) and their amplitude (5.7 ± 0.46 pA and
5.04 ± 0.27 pA, before and during fluoxetine, respectively; n = 5;
p > 0.05; Figures 4D–F). These results indicate that fluoxetine-
induced changes in GDPs frequency probably involve GABAergic
but not glutamatergic signaling.
Miniature events are generated mainly by spontaneous, action
potential independent release of GABA from fast spiking,
cannabinoid (CB) receptor-negative and regular spiking CB1
receptor-positive GABAergic interneurons. To evaluate whether
fluoxetine selectively affects a particular interneuron popula-
tion we used WIN55,212-2, a CB1/CB2 receptor agonist, to
occlude cannabinoid receptors present on axon terminals of
cholecystokinin-positive regular spiking cells. In our hands,
WIN55,212-2 was acting on CB1 receptors as demonstrated by
a previous study from the CA3 hippocampal region of new-
born rats and mice (Caiati et al., 2012). WIN55,212-2 (1μM)
per se, caused a reduction of mGPSCs frequency of 46.2 ±
21.8% (n = 5; p < 0.05) in the absence of any change in ampli-
tude. Bath application of AM 251 (5μM), a selective CB1
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FIGURE 4 | Fluoxetine increased the frequency of miniature GPSCs
but did not affect miniature EPSCs. (A) Continuous voltage clamp
recordings of mGPSCs from a holding potential of −60mV in the
presence of DNQX (20μM), D-APV (10μM), and TTX (1μM) before and
during application of fluoxetine (20μM). (B) Cumulative distribution plots
of inter event interval (IEI) and amplitude for the cell shown in A before
(black) and during (grey) application of fluoxetine. (C) Summary plots of
the mean frequency (n = 11; p = 0.002) and amplitude (n = 11; p = 0.17)
of all cells tested (±SEM). (D–F) as in (A–C) but for mEPSCs (recorded
in the presence of bicuculline, 10μM, TTX, 1μM). No significant
differences in frequency (n = 5; p = 0.5) or amplitude (n = 5; p > 0.05) of
mEPSCs were detected.
receptor antagonist, did not produce any effect on mGPSCs
amplitude (101 ± 3.2% of controls; n = 5; p > 0.05) and fre-
quency (104 ± 8.5% of controls; n = 5; p > 0.05), indicating
that CB1 receptors were not tonically active. Addition of flu-
oxetine to slices incubated for 20–30min in the presence of
WIN55,212-2, enhanced the frequency of GPSCs (from 0.40 ±
0.14Hz to 0.77 ± 0.23Hz; n = 5; p = 0.02) without significantly
modifying their amplitude (25.03 ± 2.1 pA and 28.2 ± 3.5 pA,
n = 5; before and during WIN55,212-2, respectively; p = 0.3;
Figure 5).
Therefore, while WIN55,212-2 reduced mGPSCs frequency,
fluoxetine enhanced it (Figure 5C). It should be stressed that the
percentage increase of GPSCs frequency detected when fluoxe-
tine was applied after WIN55,212-2 was similar to that obtained
when the drug was applied in the absence of WIN55,212-
2, indicating that fluoxetine acts mainly on CB1 receptor-
negative GABAergic interneurons (p = 0.2; Figure 5C). These
results further stress previous data obtained from the CA1
hippocampal region of juvenile animals, showing a selective
effect of fluoexitine on GABAergic neurotransmission from
fast spiking CB1 receptor-negative interneurons (Méndez et al.,
2012).
It is worth mentioning that the effects of fluoxetine on mGP-
SCs were independent of serotonin action since, in the presence
of citalopram, fluoxetine still enhanced mGPSCs frequency of
186 ± 29% (n = 5; p = 0.01; data not shown).
FLUOXETINE REDUCES THE FREQUENCY AND AMPLITUDE OF
SPONTANEOUSLY OCCURRING GPSCs
Next, we tested the effects of fluoxetine on the frequency
and amplitude of spontaneous action potential-dependent
GABAergic (sGPSCs) and glutamatergic (sEPSCs) currents.
UnlikemGPSCs, fluoxetine (20μM) significantly reduced the fre-
quency (from 4.7 ± 0.9Hz to 3.3 ± 0.76Hz; n = 8; p = 0.007)
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FIGURE 5 | Fluoxetine-induced increase of mGPSCs frequency does
not involve CB1 receptor-positive GABAergic interneurons. (A) Sample
traces of mGPSCs recorded in the presence of WIN55,212-2 (1μM) and
WIN55,212-2 plus fluoxetine (20μM). (B) Summary plots of the mean
frequency (n = 5; p = 0.02) and amplitude (n = 5; p = 0.3) of mGPSCs
recorded in the presence of WIN55,212-2 (white columns) and
WIN55,212-2 plus fluoxetine (gray columns) for all cells tested (±SEM). (C)
Frequency changes (as percentage of controls) induced by bath application
of WIN55,212-2 (white), fluoxetine (grey) and fluoxetine plus WIN55,212-2
(black). Note that while WIN55,212-2 depressed the frequency of mGPSCs
fluoxetine increased it. In addition, a similar percentage increase of
mGPSCs frequency occurred when fluoxetine was applied alone or in the
presence of WIN55,212-2.
and the amplitude (57 ± 7 pA to 47 ± 8 pA; n = 8; p = 0.004;
Figures 6A–C) of sGPSCs, with a relative loss of larger amplitude
events (>60 pA). The reduction in amplitude of spontaneous
events was not associated with changes in deactivation kinet-
ics, since similar decay time values were obtained for sGPSCs
recorded in the absence or in the presence of the antidepressant
(15.3 ± 0.9ms and 16.7 ± 0.7, in the absence and in the presence
of fluoxetine, respectively; n = 9; p = 0.2).
In contrast, fluoxetine failed to affect sEPSCs. The frequency of
sEPSCs was 1.34 ± 0.27Hz and 1.24 ± 0.27Hz, before and dur-
ing fluoxetine application (n = 5; p = 0.4; Figures 6D–F) and
the amplitude was 7 ± 1 pA and 6 ± 1 pA before and during
fluoxetine application (p = 0.38; Figures 6D–F).
These data further confirm a selective action of fluoxetine on
GABAergic interneurons.
To evaluate whether the effects of fluoxetine on sGPSCs did
not involve CB receptor-positive GABAergic interneurons, we
applied WIN55,212-2 (1μM). This drug significantly reduced
the frequency of sGPSCs of 31.6 ± 6% (n = 7; p < 0.001) but
not their amplitude (4 ± 4.8%; p = 0.4; Figure 7C). Then, in
another set of experiments, we incubated the slices for 20–30min
in the presence of WIN55,212-2 (1μM). Application of fluoxe-
tine in the presence of WIN55,212-2 further decreased sGPSCs
frequency (from 2.5 ± 0.7Hz to 1.8 ± 0.56Hz; n = 8; p = 0.008)
and reduced their amplitude (from 53 ± 4.5 pA to 39.9 ± 2.4 pA;
p = 0.008; Figure 7) with a selective loss of higher amplitude
events.
The similar reduction of sGPSCs frequency observed when
fluoxetine was applied alone or in the presence of WIN55,212-
2 and the reduction of amplitude detected only when fluoxe-
tine was added to WIN55,212-2, clearly indicate that fluoxetine
and WIN55,212-2 act on two different neuronal GABAergic
populations.
Fluoxetine effects on sGPSCs did not involve serotonin, since
in the presence of citalopram (1μM) the drug still caused a sig-
nificant reduction of both sGPSCs frequency (55.5 ± 12%; n = 5;
p < 0.05) and amplitude (36 ± 4%; n = 5; p < 0.05; data not
shown).
FLUOXETINE REDUCES THE FIRING RATE OF GABAergic
INTERNEURONS AND PRINCIPAL CELLS
In analogy with the synchronized activity generated in the dis-
inhibited hippocampus (De la Prida et al., 2006), GDPs emerge
when a sufficient number of cells fire and the excitability of
the network attains a certain threshold within a restricted time
window (Ben-Ari et al., 2012). Although the entire hippocam-
pal network possesses the capacity to generate GDPs, the CA3
area is particularly well equipped because of its extensive gluta-
matergic recurrent collaterals and spontaneous intrinsic bursts
that can drive other neurons to fire (Sipilä et al., 2005; Safiulina
et al., 2008). Therefore, in cell attach experiments (to preserve
the intracellular milieu of the recorded neurons), we measured
the spontaneous firing rate of stratum radiatum GABAergic
interneurons and pyramidal cells. Bath application of fluoxetine
reversibly slowed down the firing rate of both principal cells (from
1.57 ± 0.74Hz to 0.56 ± 0.37Hz; n = 5; p < 0.05; Figures 8A,B)
and interneurons (from 2.7 ± 1.7Hz to 0.33 ± 0.22Hz; n = 5;
p < 0.05; Figures 8C,D).
The fluoxetine-induced reduction of spontaneous firing may
severely alter network excitability and GDPs generation.
DISCUSSION
The present results clearly indicate that the acute exposure of
immature hippocampal slices to fluoxetine, a major antidepres-
sant widely used for the treatment of mood disorders, severely
alters GABAA-mediated network activity under the form of GDPs
which, as already mentioned, represent a hallmark of devel-
opmental circuits. This effect appears to be dependent on the
reduced release of GABA from subpopulations of GABAergic
interneurons not expressing CB1 receptors.
The effects of fluoxetine on GDPs were not indirectly medi-
ated via serotonin or other amines known to be the targets of
the antidepressant, since they persisted following occlusion of
serotonin uptake with citalopram or blockade of monoamine,
Frontiers in Cellular Neuroscience www.frontiersin.org May 2013 | Volume 7 | Article 63 | 6
Caiati and Cherubini Fluoxetine and GDPs
FIGURE 6 | Fluoxetine reduced the frequency and amplitude of
spontaneous action potential-dependent GPSCs but did not affect
AMPA-mediated EPSCs. (A) Continuous voltage clamp recordings of
sGPSCs detected at −60mV in the presence of DNQX (20μM) and
D-APV (10μM), before and during application of fluoxetine (20μM).
(B) Cumulative distribution plots of inter event interval (IEI) and
amplitude for the cell shown in (A) before (black) and during (grey)
application of fluoxetine. (C) Summary plots of the mean frequency
(n = 8; p = 0.007) and amplitude (n = 8; p = 0.004) of all cells tested
(±SEM). (D–F) As in (A–C) but for sEPSCs. No significant
differences in frequency (n = 5; p = 0.4) or amplitude (n = 5;
p = 0.38) were detected.
histamine and muscarinic receptors with asenapine. Unlike flu-
oxetine, both citalopram and asenapine enhanced GDPs fre-
quency probably by directly interfering with “ambient” serotonin
present at low levels in the extracellular space. Interestingly,
the concentration of fluoxetine needed to affect GABA release
was higher than that necessary to impair serotonin transporters
(Kobayashi et al., 2008), suggesting a concentration-dependent
effect on different targets. The concentration we used (close to
the IC50 value), could be clinically relevant since, due to a very
slow elimination (Henry et al., 2005), during chronic treatment
the drug accumulates in the brain reaching a concentration 20
times higher than that present in the plasma (Karson et al.,
1993).
GDPs are generated by the synergistic action of GABA and glu-
tamate, both of them depolarizing and excitatory (Bolea et al.,
1999; Ben-Ari et al., 2012) and therefore, their depression by
fluoxetine may involve changes of glutamatergic, GABAergic
synaptic transmission or both. We can exclude the involvement of
glutamate, since spontaneous AMPA-mediated EPSCs were not
affected by the drug. It is therefore likely that major targets of
the antidepressant are GABAergic interneurons. Fluoxetine was
recently shown to reduce GABA release from PV-positive fast
spiking GABAergic interneurons in the hippocampus of juve-
nile animals (Méndez et al., 2012). Although PV-positive basket
cells certainly contribute to the spontaneous action potential-
dependent release of GABA (Freund and Katona, 2007) we
cannot exclude the participation of other interneuron subtypes.
However, the similar degree of depression in GPSCs amplitude
and frequency observed when slices were exposed to fluoxetine
or fluoxetine plus WIN55,212-2, indicates, in line with the results
of Méndez et al. (2012), that CB1-positive interneurons were not
affected.
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FIGURE 7 | Fluoxetine-induced reduction of sGPSCs frequency and
amplitude does not involve CB1 receptor-positive GABAergic
interneurons. (A) Sample traces of sGPSCs recorded in the presence of
WIN55,212-2 (1μM) and WIN55,212-2 plus fluoxetine (20μM). (B)
Summary plots of the mean frequency (n = 8; p = 0.008) and amplitude
(n = 7; p = 0.008) of sGPSCs recorded in the presence of WIN55,212-2
(white columns) and WIN55,212-2 plus fluoxetine (gray columns) for all
cells tested (±SEM). (C) Frequency and amplitude changes (as percentage
of controls) induced by bath application of WIN55,212-2 (white), by
fluoxetine (grey) and fluoxetine plus WIN55,212-2 (black). Note that while
WIN55,212-2 depressed only the frequency of sGPSCs, fluoxetine
depressed both the frequency and the amplitude. In addition, fluoxetine
depressed to a similar extent the amplitude and the frequency of sGPSCs
when applied alone or in the presence of WIN55,212-2.
Fluoxetine has been reported to positively modulate via a
novel allosteric site GABAA receptors (Robinson et al., 2003).
However, in the present case this is unlikely since the drug exerted
a depressant and not a potentiating action on the frequency
and amplitude of spontaneous GPSCs. In addition, the lack of
fluoxetine-induced changes in the deactivation kinetics of spon-
taneous events allow excluding a direct effect of the drug on the
gating properties of GABAA receptors. The depressant effect of
fluoxetine is probably presynaptic and may reflect the preferen-
tial loss of higher amplitude events following the impairment
of synchronous release of GABA from distinct release sites. At
the concentration used, the drug may inhibit vesicle exocytosis
(Henkel et al., 2010) by interfering with calcium entry through
P/Q (Pfenninger et al., 2003) or other types of calcium chan-
nels (Deák et al., 2000; Traboulsie et al., 2006). This may lead to
a reduced cell excitability. The reduction of spontaneous firing
rate of principal cells and interneurons in cell attach exper-
iments strengthens this hypothesis. Fluoxetine may affect cell
FIGURE 8 | Fluoxetine reduces the firing rate of principal cells and
interneurons. (A) cell attach recordings of a pyramidal cell before, during
and after (Wash) application of fluoxetine (20μM). (B) Population graph of
the firing frequency of pyramidal cells (n = 5) before (Cont), during (Fluo)
and after application of fluoxetine (Wash). Columns represent the mean,
bars the SEM. The effects of fluoxetine were significantly different from
controls (p < 0.05). (C,D) as in (A,B) but for GABAergic interneurons in
stratum radiatum (n = 5; p < 0.05).
excitability also by inhibiting voltage-gated sodium (Lenkey et al.,
2006; Igelström and Heyward, 2012) and potassium channels
(Yeung et al., 1999). Although inhibition of potassium currents
should enhance cell excitability, in some cases (i.e., impairment
of the delayed rectifier) it may prevent membrane potential from
returning to a level where sodium channels can de-inactivate, thus
reducing the availability of sodium channels and repetitive firing.
This mechanism has been suggested to underline the action of the
antiepileptic drug levetiracetam (Madeja et al., 2003).
As already mentioned, GDPs emerge when a sufficient num-
ber of cells fire and the excitability of the network attains a certain
threshold within a restricted time window. Therefore, it is rea-
sonable to believe that a reduced neuronal excitability may lead to
a reduction of cell firing, network desynchronization and GDPs
depression.
It is worth mentioning that, in the present experiments,
fluoxetine exerted opposite effects on spontaneous calcium-
independent (miniature) and calcium-dependent release of
GABA. While we cannot exclude the possibility that the
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antidepressant controls mini and spontaneous action potential-
dependent events through different mechanisms, as a unifying
view we can hypothesize that the elevated extracellular levels
of GABA, following the asynchronous release may reduce cell
excitability and synchronicity via shunting inhibition. A simi-
lar perspective has been put forward by Méndez et al. (2012) to
explain the fluoxetine-induced increase of miniature GABAergic
currents associated with a reduction of GABA release from fast
spiking basket cells. According to these authors, the synergis-
tic reduction of synchronous release from fast spiking cells and
the enhanced spontaneous asynchronous release of GABA can
deteriorate spike-timing precision and γ oscillations. However,
in our case, this is unlikely since, early in postnatal life, ambi-
ent GABA exerts a depolarizing and excitatory action on target
cells (Marchionni et al., 2007). Therefore, fluoxetine-induced ele-
vation of the extracellular GABA levels should be associated with
an increase and not a decrease in cell excitability.
Whatever is the mechanism, it is clear that fluoxetine severely
affects correlated network activity in the developing hippocam-
pus. Since calcium transients associated with GDPs act as coinci-
dent detector signals for enhancing synaptic efficacy at emerging
glutamatergic (Mohajerani et al., 2007) and GABAergic synapses
(Kasyanov et al., 2004), a disruption of GDPs may have serious
consequences on the construction and functional organization of
the hippocampal networks.
Although the present experiments do not directly demonstrate
whether the chronic maternal treatment with fluoxetine alters
neuronal circuits and brain development in pups, nonetheless,
they highlight the crucial role of the antidepressant on GABAergic
signaling in the immature hippocampus. While further exper-
iments in pups from chronically treated mothers would help
clarifying this point, considering the crucial role of GABA in
the developing networks, caution should be taken in treating
pregnant woman affected by mood disorders with fluoxetine.
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